Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib for relapsed or refractory primary central nervous system lymphoma
ISRCTN90634455Phase 2Recruiting
- Sponsor
- University of Birmingham
- Start
- Oct 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of zanubrutinib in primary central nervous system lymphoma (PCNSL) and Diffuse Large B-Cell Primary Central Nervous System Lymphoma, sponsored by University of Birmingham. Primary endpoint: Overall response after two cycles. Started Oct 2022; status: recruiting.
02
Drugs
zanubrutinib
03
Conditions
primary central nervous system lymphoma (PCNSL)Diffuse Large B-Cell Primary Central Nervous System Lymphoma
Beyond the preview
Go deeper on ISRCTN90634455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN90634455.